Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Val30Met: Tafamidis Then Tafamidis	38
Overall Study	STARTED	Val30Met: Placebo Then Tafamidis	37
Overall Study	STARTED	NonVal30Met: Tafamidis	18
Overall Study	Treated	Val30Met: Tafamidis Then Tafamidis	38
Overall Study	Treated	Val30Met: Placebo Then Tafamidis	37
Overall Study	Treated	NonVal30Met: Tafamidis	18
Overall Study	COMPLETED	Val30Met: Tafamidis Then Tafamidis	32
Overall Study	COMPLETED	Val30Met: Placebo Then Tafamidis	28
Overall Study	COMPLETED	NonVal30Met: Tafamidis	8
Overall Study	NOT COMPLETED	Val30Met: Tafamidis Then Tafamidis	6
Overall Study	NOT COMPLETED	Val30Met: Placebo Then Tafamidis	9
Overall Study	NOT COMPLETED	NonVal30Met: Tafamidis	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00925002/flow